BridgeBio

Metallic arrow symbols illuminated by blue and magenta lights forming a graph on blue and magenta background
Biotech

BridgeBio's muscle weakness data impress ahead of FDA filing

BridgeBio took another step toward the approval of its muscle weakness candidate, reporting phase 3 efficacy data that analysts called impressive.
Nick Paul Taylor Mar 12, 2026 10:30am
winnter trophy star

BridgeBio's calcium deficiency candidate scores phase 3 win

Oct 29, 2025 7:00am
parachute chutes

Former FDA deputy joins AI biotech's board—Chutes & Ladders

Mar 21, 2025 8:30am
heart monitor

BridgeBio touts extension study data for ATTR-CM drug acoramidis

Nov 18, 2024 3:38pm
Heart drawn in the sand on the beach

BridgeBio touts case for acoramidis with post hoc study analysis

Sep 30, 2024 9:37am
Photo of a carnival ride that swings people in elevated chairs caught in motion

BridgeBio’s offshoot GondolaBio launches with $300M

Aug 21, 2024 11:36am